Something shifted in healthcare AI in 2026. The conversation moved from what AI might one day do to what it is already doing inside real healthcare operations: documenting visits, answering clinical questions, running front offices, supporting coverage decisions, and keeping providers connected to patients between appointments.
The companies best positioned for 2027 share a pattern. They solve a specific problem in care delivery, clinical work, operations, or research. They can point to something that actually happened in 2026.
And they treat clinical oversight as part of the product, not an afterthought.
This Trusted AI News list highlights twelve health tech startups to watch in 2027. It is an editorial assessment of the companies building the next operating layers of healthcare.
How we selected these startups
- They solve a specific healthcare problem. Broad AI claims are not enough. The product has to make a meaningful difference in care delivery, clinical work, operations, diagnostics, or research.
- They represent distinct parts of the market. A useful list is not twelve versions of the same documentation tool.
- They showed verifiable momentum in 2026. A regulatory milestone, a market expansion, a product launch, or adoption that can be pointed to.
- They reflect where healthcare is heading. More continuous, more AI-supported, and with clinicians staying in control of clinical decisions.
The 12 health tech startups to watch in 2027
1. Actuvi
Best for: building AI-supported care inside the provider’s own ecosystem
Care is moving beyond the clinic, and Actuvi focuses on helping existing providers extend their own care. Its platform lets providers, clinics, and hospitals run their own remote therapeutic monitoring (RTM), remote patient monitoring (RPM), and advanced primary care management (APCM) programs around how their own teams already work, combining digital intake, multilingual consent, scheduled assessments, PROMs and PREMs, messaging, care plans, automated charting, and clinical-threshold workflows in one connected environment.
The patient, the care team, and the data stay inside the provider’s ecosystem.
The platform brings clinic-specific care pathways, longitudinal patient information, and care-team workflows into one environment. Its AI-supported tools help organize that information for review, while providers remain responsible for clinical decisions.
The reason to watch Actuvi in 2027 is the data foundation. Consistent collection builds a longitudinal baseline for each patient rather than isolated snapshots from appointments. That baseline is the groundwork for a more proactive and predictive model of care, and Actuvi is expanding its programs across specialties and geographies.
2. OpenEvidence
Best for: clinical answers at the point of care
OpenEvidence has become a default AI reference for U.S. clinicians, offering evidence-based answers drawn from the medical literature under content agreements with publishers including NEJM Group. A national study published in JAMA in October 2026 counted 952,008 U.S. clinicians submitting 271 million queries on the platform between January 2024 and June 2026, with monthly active users growing from a few hundred to more than 700,000 over that period, most of them asking about treatment and management decisions.
The question for 2027 is what that position turns into. A tool physicians already reach for at the point of care is a strong foundation for deeper workflow integration, and how OpenEvidence handles that expansion will say a lot about whether clinical information remains a standalone product or becomes infrastructure.
3. Abridge
Best for: ambient clinical documentation at enterprise scale
Abridge turned ambient listening during the clinical visit into structured documentation, and it has scaled that capability across major health systems. In 2026 it moved beyond the note: more than 300 enterprise health systems adopted its AI decision support, built with Wolters Kluwer’s UpToDate, within months of its April launch, and the company is making it available to every clinician at its partner systems, part of a stated ambition to become an operating system for medicine.
Watch Abridge in 2027 for the scope question. Documentation is the entry point; the test is how far the platform extends beyond the visit note into the clinical work that follows it.
4. Suki
Best for: AI agents across health systems
Suki began in ambient documentation and has been widening its ambition. In October 2026 it announced a new phase focused on building and scaling AI agents for health systems and health-tech companies, moving from recording the visit toward acting on the work around it.
Suki’s trajectory is one of the clearest tests of where clinical AI goes next: whether the assistants that earned trust by taking notes can take on broader tasks inside health-system workflows.
5. Hippocratic AI
Best for: patient-facing AI agents built around safety
Hippocratic AI builds generative AI agents for non-diagnostic, patient-facing work: follow-up calls, chronic care check-ins, scheduling, and navigation. After announcing an expansion across healthcare verticals in January 2026, it signed an expanded multi-year partnership with WellSpan Health in July, where its generative AI agent, Ana, is growing from appointment scheduling into post-discharge follow-up and chronic disease check-ins, with each new use developed under WellSpan’s governance and safety structures.
The company has made clinical safety its central pitch, and 2027 will test whether that positioning holds as deployment widens to more organizations, more patients, and more use cases.
6. EliseAI
Best for: front-office automation in healthcare operations
EliseAI applies conversational AI to the operational work that buries front offices: answering patient calls, scheduling appointments, and managing follow-ups around the clock. In October 2026 it was named a preferred partner of Nextech, the specialty-practice software provider, to bring its voice AI agent to specialty practices, answering every patient call at any hour and working directly inside the practice’s own system.
Administrative automation is where many healthcare organizations start with AI, because the return is visible quickly. EliseAI’s healthcare growth will show how far that entry point carries.
7. Vocca
Best for: AI reception for medical practices
Vocca gives medical practices an AI phone assistant that answers patient calls, handles scheduling, and manages routine requests. In October 2026 the company reported growing from 2,000 to 15,000 medical practitioners in a year, across 1,500 practices and twenty specialties in the U.S. and Europe.
That adoption curve makes Vocca worth watching: independent practices are often the last to adopt new software, and an AI tool spreading through them this fast suggests the front-desk problem is bigger than the industry assumed.
8. Cohere Health
Best for: AI-assisted prior authorization
Cohere Health applies AI to utilization management and prior authorization, one of the most contested workflows in American healthcare. In 2026 it was among six companies selected by CMS as participants in the WISeR model, which uses enhanced technology alongside human clinical review to assess medical necessity for selected services in traditional Medicare.
Prior authorization is where questions about AI’s role in coverage decisions get answered in practice. How Cohere and its peers perform under that scrutiny through 2027 will shape the rules everyone else works under.
9. Neko Health
Best for: preventive health scanning at scale
Neko Health sells a full-body health scan that combines proprietary sensors, software, and clinician interpretation to catch problems before they become crises. The company opened its first U.S. location in New York in September 2026 after more than 25,000 New Yorkers joined the waitlist, with Miami, Washington, D.C., and San Francisco planned to follow.
The open question is portability. Neko proved demand in Europe; 2027 will show whether preventive scanning at this price point becomes part of everyday American healthcare or stays a premium niche.
10. Pathos AI
Best for: agentic AI drug development
Pathos AI is applying agentic AI to drug development, pairing computational models trained on more than 200 petabytes of multimodal oncology data with its own clinical-stage pipeline. In August 2026 it signed a global licensing agreement with Alphamab Oncology for JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate.
Most AI in drug discovery stops at prediction. Pathos is testing whether AI can run more of the development process itself, which makes its pipeline readouts some of the most informative in the field.
11. Nouscom
Best for: cancer interception
Nouscom develops immunotherapies designed to intercept cancer before it takes hold. In October 2026 it presented long-term clinical data in Lynch syndrome carriers at ESMO and set out plans to take its lead candidate through a registration-enabling trial.
Interception is a different bet than treatment: prevent the disease rather than fight it late. A pivotal trial makes 2027 the year that bet starts producing definitive answers.
12. NeuroXess
Best for: implantable brain-computer interfaces
NeuroXess, based in Shanghai, is developing implantable brain-computer interfaces intended to restore communication and movement for patients with severe neurological conditions. In July 2026 it began recruiting a multicenter clinical trial of a fully implanted, wireless brain-computer interface for upper-limb function in patients with spinal cord injury.
Brain-computer interfaces have spent years as demonstrations. NeuroXess’s push into trials and manufacturing is a sign the field is starting to treat them as medical products.
The trends shaping health tech in 2027
- AI is becoming the operating layer. The strongest companies no longer sell AI as a feature; they build it into how documentation, coverage decisions, front offices, and between-visit care actually run.
- AI agents are moving from documentation to action. The companies that won trust taking notes are now being asked to do the work around the note.
- Prevention keeps gaining ground. Scanning, interception, and earlier detection are moving from premium experiments toward everyday care on the strength of long-term economics.
- Oversight is becoming a feature. Regulators and buyers increasingly ask who reviews the AI’s work, and companies with a clear answer have an advantage.
- Deployment beats novelty. The companies that mattered in 2026 were embedded in real workflows rather than demonstrating potential.
Frequently asked questions
What are the health tech startups to watch in 2027?
The companies in this guide span care delivery, clinical information, documentation, AI agents, front-office operations, prior authorization, preventive scanning, drug development, cancer interception, and brain-computer interfaces. What links them is verified momentum in 2026 and a product direction that matches where healthcare is heading.
How were these companies selected?
Selection was based on four criteria: a specific healthcare problem, a distinct place in the market, verifiable momentum in 2026 such as a regulatory milestone or market expansion, and a direction that reflects more continuous, AI-supported care with clinicians in control.
Why does clinical oversight matter in health tech AI?
Healthcare decisions carry real consequences, so the companies worth watching build review into the product: clinicians stay responsible for clinical decisions, and regulators and buyers increasingly ask who checks the AI’s work. Companies with a clear answer earn trust faster.
How is AI changing health tech startups?
AI is moving from a feature to the operating layer. The strongest companies use it to organize clinical information, reduce administrative work, support earlier detection, and extend care between visits, while keeping clinicians responsible for clinical decisions.
Why does between-visit care matter?
Most of a patient’s health happens outside the exam room. Companies that help providers stay connected to patients between visits build a longitudinal picture of health that single appointments cannot provide, and that picture is the foundation for earlier, more proactive care.
The through line for 2027
The companies on this list are worth watching because they are building toward a healthcare system that does more than digitize existing processes. The larger opportunity is to connect clinical information, operational workflows, and patient experiences in ways that help teams act earlier and more effectively.
For Actuvi, that means helping providers run AI-supported care programs inside their own ecosystems, capturing a more complete picture of patient outcomes over time. For the wider market, it means moving from isolated tools toward healthcare that is more proactive, more precise, and easier to navigate.
That is the direction health tech is taking into 2027.
